Kidney Cancer Research
Targeted Therapy–Immunotherapy Combinations Effective for Advanced Kidney CancerPosted: March 19, 2019
In two clinical trials, combination treatments that included an immune checkpoint inhibitor and axitinib (Inlyta) led to better outcomes for patients with advanced kidney cancer than treatment with sunitinib (Sutent), the standard initial therapy.
Some Children with Wilms Tumor Can Receive Less Therapy, Study SuggestsPosted: May 23, 2018
Results from an NCI-sponsored clinical trial may point to an important change in how some children with advanced Wilms tumor, a form of kidney cancer, are treated.
FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney CancerPosted: May 10, 2018
FDA has approved the combination of two immunotherapy drugs, nivolumab (Opdivo) and ipilimumab (Yervoy), as an initial treatment for some patients with advanced kidney cancer. Learn how this approval will affect patient care.
Cabozantinib Approval Expands Initial Treatment Options for Advanced Kidney CancerPosted: February 27, 2018
The Food and Drug Administration has approved cabozantinib (Cabometyx®) as an initial treatment for patients with advanced renal cell carcinoma, the most common type of kidney cancer.
Studies Highlight Potential of Targeting HIF-2 in Kidney CancerPosted: September 29, 2016
Two new studies suggest that a new class of drugs can effectively target a molecular driver of the most common type of kidney cancer.
Two New Therapies Approved by FDA for Advanced Kidney CancerPosted: June 3, 2016
The FDA has approved two drugs, cabozantinib and lenvatinib, for patients whose advanced kidney cancers have progressed after prior treatment with antiangiogenic therapies.
Sunitinib and Sorafenib Ineffective as Adjuvant Therapies for Kidney CancerPosted: April 8, 2016
Results from a recent clinical trial show that post-surgical therapy with two anti-angiogenesis drugs does not improve progression-free survival for patients with kidney cancer and may cause serious side effects.
TCGA findings on papillary renal cell carcinoma and prostate cancerPosted: November 5, 2015
Researchers with The Cancer Genome Atlas (TCGA) report new findings on papillary renal cell carcinoma and prostate cancer.
Rare kidney tumor provides insights on role of metabolic changes in cancerPosted: August 21, 2014
Researchers in The Cancer Genome Atlas (TCGA) Network have uncovered a number of new findings about the biology and development of a rare form of kidney cancer. They found that the disease – chromophobe renal cell carcinoma – stems in part from alterations in genes in the mitochondria, the cell’s energy supplier.